Research ExplorerPublicationsFrequent homogeneous HER-2 amplification in primary and meta...

Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus.

Standard

Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. / Reichelt, Uta; Duesedau, Peer; Tsourlakis, Maria Ch; Quaas, Alexander; Link, Björn-Chr.; Schurr, Paulus; Kaifi, Jussuf; Gros, Stephanie; Yekebas, Emre F.; Marx, Andreas; Simon, Ronald; Izbicki, Jakob R.; Sauter, Guido.

In: MODERN PATHOL, Vol. 20, No. 1, 1, 2007, p. 120-129.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Reichelt, U, Duesedau, P, Tsourlakis, MC, Quaas, A, Link, B-C, Schurr, P, Kaifi, J, Gros, S, Yekebas, EF, Marx, A, Simon, R, Izbicki, JR & Sauter, G 2007, 'Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus.', MODERN PATHOL, vol. 20, no. 1, 1, pp. 120-129. <http://www.ncbi.nlm.nih.gov/pubmed/17143264?dopt=Citation>

APA

Reichelt, U., Duesedau, P., Tsourlakis, M. C., Quaas, A., Link, B-C., Schurr, P., Kaifi, J., Gros, S., Yekebas, E. F., Marx, A., Simon, R., Izbicki, J. R., & Sauter, G. (2007). Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. MODERN PATHOL, 20(1), 120-129. [1]. http://www.ncbi.nlm.nih.gov/pubmed/17143264?dopt=Citation

Vancouver

Reichelt U, Duesedau P, Tsourlakis MC, Quaas A, Link B-C, Schurr P et al. Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. MODERN PATHOL. 2007;20(1):120-129. 1.

Bibtex

@article{4b6bc25c708f473599971c9545ac150a,
title = "Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus.",
abstract = "HER-2 is the target for antibody based treatment of breast cancer (Herceptin). In order to evaluate the potential role of such a treatment in esophageal cancers, HER-2 amplification and overexpression was investigated in primary and metastatic cancers of the esophagus. A tissue microarray was constructed from 255 primary esophageal cancers (110 adenocarcinomas and 145 squamous cell carcinomas), 89 nodal and 33 distant metastases. Slides were analyzed by immunohistochemistry (HercepTest; DAKO) and fluorescence in situ hybridization (FISH; PathVysion; Vysis-Abbott) for HER-2 amplification and overexpression. Amplification was seen in 16/110 (15%) adenocarcinomas and in 7/145 (5%) squamous cell carcinomas. There was a strong association between HER-2 amplification and overexpression, especially in adenocarcinomas (P",
author = "Uta Reichelt and Peer Duesedau and Tsourlakis, {Maria Ch} and Alexander Quaas and Bj{\"o}rn-Chr. Link and Paulus Schurr and Jussuf Kaifi and Stephanie Gros and Yekebas, {Emre F.} and Andreas Marx and Ronald Simon and Izbicki, {Jakob R.} and Guido Sauter",
year = "2007",
language = "Deutsch",
volume = "20",
pages = "120--129",
journal = "MODERN PATHOL",
issn = "0893-3952",
publisher = "NATURE PUBLISHING GROUP",
number = "1",

}

RIS

TY - JOUR

T1 - Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus.

AU - Reichelt, Uta

AU - Duesedau, Peer

AU - Tsourlakis, Maria Ch

AU - Quaas, Alexander

AU - Link, Björn-Chr.

AU - Schurr, Paulus

AU - Kaifi, Jussuf

AU - Gros, Stephanie

AU - Yekebas, Emre F.

AU - Marx, Andreas

AU - Simon, Ronald

AU - Izbicki, Jakob R.

AU - Sauter, Guido

PY - 2007

Y1 - 2007

N2 - HER-2 is the target for antibody based treatment of breast cancer (Herceptin). In order to evaluate the potential role of such a treatment in esophageal cancers, HER-2 amplification and overexpression was investigated in primary and metastatic cancers of the esophagus. A tissue microarray was constructed from 255 primary esophageal cancers (110 adenocarcinomas and 145 squamous cell carcinomas), 89 nodal and 33 distant metastases. Slides were analyzed by immunohistochemistry (HercepTest; DAKO) and fluorescence in situ hybridization (FISH; PathVysion; Vysis-Abbott) for HER-2 amplification and overexpression. Amplification was seen in 16/110 (15%) adenocarcinomas and in 7/145 (5%) squamous cell carcinomas. There was a strong association between HER-2 amplification and overexpression, especially in adenocarcinomas (P

AB - HER-2 is the target for antibody based treatment of breast cancer (Herceptin). In order to evaluate the potential role of such a treatment in esophageal cancers, HER-2 amplification and overexpression was investigated in primary and metastatic cancers of the esophagus. A tissue microarray was constructed from 255 primary esophageal cancers (110 adenocarcinomas and 145 squamous cell carcinomas), 89 nodal and 33 distant metastases. Slides were analyzed by immunohistochemistry (HercepTest; DAKO) and fluorescence in situ hybridization (FISH; PathVysion; Vysis-Abbott) for HER-2 amplification and overexpression. Amplification was seen in 16/110 (15%) adenocarcinomas and in 7/145 (5%) squamous cell carcinomas. There was a strong association between HER-2 amplification and overexpression, especially in adenocarcinomas (P

M3 - SCORING: Zeitschriftenaufsatz

VL - 20

SP - 120

EP - 129

JO - MODERN PATHOL

JF - MODERN PATHOL

SN - 0893-3952

IS - 1

M1 - 1

ER -